GLP-1-driven vitamin deficiency linked to rare brain disorder: Study
- Researchers identified 15 cases of Wernicke encephalopathy, a rare brain disorder caused by severe vitamin B1 deficiency, in people using GLP-1 receptor agonist medications such as semaglutide and tirzepatide.
- Most patients experienced gastrointestinal symptoms or nutritional problems including weight loss, vomiting, and loss of appetite, with more reported cases among GLP-1 medication users than others, though causation remains unproven.
15 Articles
15 Articles
Haber 7 - A serious new risk has emerged regarding weight-loss injections, which have become widespread in recent years. Severe and prolonged vomiting, which can occur in some individuals using these injections, can lead to insufficient nutrient intake and, in particular, vitamin B1 deficiency.
Experts characterize the complication as rare, but point out its severity and its connection with severe vomiting, loss of appetite and vitamin B1 deficiency. A rare and serious brain disorder has been detected in a small number of people taking GLP-1 drugs for weight loss and diabetes, according to a new study. A total of 15 cases of Wernicke encephalopathy were identified in the period 2023-2024, during the U.S. Food and Drug Administration's …
A new study has revealed that a small percentage of people using GLP-1 group weight loss and diabetes medications have been diagnosed with a rare but serious brain disease. In an Israel-based study, approximately 15 cases of Wernicke syndrome (Wernicke encephalopathy) were identified in 2023-2024 by examining adverse event reports from the US Food and Drug Administration (FDA) and related literature. Read more This section contains reference poi…
Coverage Details
Bias Distribution
- 82% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
